Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as RO4929097
RG4733 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| cohort 1 | EXPERIMENTAL | - |
| cohort 2 | EXPERIMENTAL | - |
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RO4929097 | DRUG | 80mg po daily, 3 days on 4 days off schedule |
| RG4733 | DRUG | Administered orally daily at ascending doses to successive cohorts of patients |
Inclusion Criteria: * adult patients, \>/= 18 years of age * stage IIIB/IV recurrent or refractory non-small cell lung cancer * at most 2 lines of prior therapy in the metastatic setting (first line: platinum containing regimen and bevacizumab; second line: EGFR-targeted therapy) * ECOG performance...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
RG4733 is an investigational small molecule being developed for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is being studied in the oncology therapeutic area for patients with advanced solid tumors.
RG4733 is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded under the ticker symbol RHHBY on the OTC market.
RG4733 is in Phase 1 clinical development. It has completed a Phase 1 trial, and it remains an investigational drug that is not yet approved for any use.
RG4733 has one completed clinical trial, identified as NCT00532090. This was a multiple ascending dose study in patients with advanced solid tumors, conducted in the United States with 110 participants aged 18 years and older.
Yes, RG4733 is also referred to as R4733. The clinical trial NCT00532090, titled 'A Multiple Ascending Dose Study of R4733 in Patients With Advanced Solid Tumors,' uses the R4733 name for the same drug.